Washington · Nonprofit
CANCER RESEARCH AND BIOSTATISTICS
CANCER RESEARCH AND BIOSTATISTICS (Washington) receives grants from 10 organizations whose IRS filings report $64,087,337 to it, the largest being FRED HUTCHINSON CANCER RESEARCH CENTER ($36,981,089). 7 of them have funded it in more than one year.
- Revenue FY2024
- $11M
- Funders on record
- 10
- Grants received
- $64M
- Net assets
- $5.4M
What Cancer Research and Biostatistics does
Mission
To help conquer cancer and other diseases through the application of biostatistical principles and innovative data management methods.
As stated on its FY2024 Form 990.
Programs
Cancer research & biostatistics (crab) is a national leader in designing and managing oncology clinical trials. Crab is the statistical center for swog (the largest nci cooperative group). It is crab's goal to provide support and statistical consultation for study design, protocol development, research data analysis, manuscript writing, and presentations at major conferences in oncology research. Crab values the long-standing relationships that it has with organizations to work, support and discover new and improved treatments for cancer patients and continues to make research alliances with leading research consortia, cancer centers, and industry. Crab is the leader of the pancreatic cancer research team (pcrt), a consortium of more than 40 clinics worldwide established for biotech and pharmaceutical companies looking to develop new agents for patients with pancreas cancer.
$8,040,048 spent$3,459,087 earned by the program100% of program spendingIn 2024, crab continued to provide ongoing support through excellent training to early investigators and clinical research associates.
$16,484 spent$14,942 earned by the program0% of program spending
The 2 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $8,056,532.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2021 to 2022, from $8.4M to $12M (+47%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2017 52% · 2018 48% · 2019 50% · 2020 61% · 2021 61% · 2022 1% · 2023 70% · 2024 69%. Grants only. Government contracts and fees sit inside program revenue.
69% of CANCER RESEARCH AND BIOSTATISTICS’s revenue is contributions — more reliant on donations than three-quarters of its peers (7% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Hoering Antje
President and CEO
As listed on its FY2024 Form 990.
Who funds it, year by year
2017 → 2023: the base narrowed from 6 funders to 2 funders, grant income rose $5.9M → $8.4M.
2 of 10 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 0% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of CANCER RESEARCH AND BIOSTATISTICS’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
CANCER RESEARCH AND BIOSTATISTICS leans on a few funders — its largest provides 58% of grant income and the top three 99%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
100% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund CANCER RESEARCH AND BIOSTATISTICS.
Largest funder’s share by year: 2017 95% · 2018 98% · 2019 99% · 2020 99% · 2021 100% · 2022 67% · 2023 100% — growing more concentrated.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
43% of CANCER RESEARCH AND BIOSTATISTICS's funders are still giving 3 years after their first grant; 70% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
98% of CANCER RESEARCH AND BIOSTATISTICS's grant income comes from Washington funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $104k arriving through sponsors registered in 2 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
CANCER RESEARCH AND BIOSTATISTICS's funding has concentrated — grant income rose while the number of funders held roughly flat.
this organization peer median middle 50% of peers· 4,580 health nonprofits $10M–$100M, FY2024
Government funding CANCER RESEARCH AND BIOSTATISTICS receives
Grants and contracts to this organization from federal (USASpending) and state checkbooks, reconciled to its EIN. $340k on record.
- Department of Veterans Affairs$325k
- Department of Health and Human Services$15k
Federal grants vs contracts are distinguished; state line items keep their reported category. Matched by name + geography (the BMF), so coverage is partial and precision-first.
Organizations like CANCER RESEARCH AND BIOSTATISTICS
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Washington
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
69% of spending goes to programs.
Governance
Public support
99%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Screen this organization
A dated, signed PDF of the compliance screen for CANCER RESEARCH AND BIOSTATISTICS: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds CANCER RESEARCH AND BIOSTATISTICS?
- CANCER RESEARCH AND BIOSTATISTICS (Washington) receives grants from 10 organizations whose IRS filings report $64,087,337 to it, the largest being FRED HUTCHINSON CANCER RESEARCH CENTER ($36,981,089). 7 of them have funded it in more than one year.
- How many funders does CANCER RESEARCH AND BIOSTATISTICS have?
- IRS filings report 10 organizations giving $64,087,337 in grants to CANCER RESEARCH AND BIOSTATISTICS, 7 of which have funded it in more than one year.
- Who is the largest funder of CANCER RESEARCH AND BIOSTATISTICS?
- FRED HUTCHINSON CANCER RESEARCH CENTER is the largest funder on record, with $36,981,089 in grants. The full list of funders is on this page.
- How can an organization like CANCER RESEARCH AND BIOSTATISTICS find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Washington. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
Play a game about who funds Cancer Research and Biostatistics →
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 10 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing